
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8297904/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Dose-Dependent Inhibitory Effect of Rosuvastatin in Japanese Patients with Acute Myocardial Infarction on Serum Concentration of Matrix Metalloproteinases–INVITATION Trial–. Journal of Atherosclerosis and Thrombosis, 2022, 29, 229-241.	2.0	1
2	Dynapenia is an independent predictor of cardio-cerebrovascular events in patients undergoing hemodialysis. Heart and Vessels, 2022, , 1.	1.2	6
3	Severe obstructive sleep apnea is associated with coronary microvascular dysfunction and obstruction in patients with ST-elevation myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 645-652.	1.0	3
4	Effects of Statin Plus Ezetimibe on Coronary Plaques in Acute Coronary Syndrome Patients with Diabetes Mellitus: Sub-Analysis of PRECISE-IVUS Trial. Journal of Atherosclerosis and Thrombosis, 2021, 28, 181-193.	2.0	6
5	Murine neonatal ketogenesis preserves mitochondrial energetics by preventing protein hyperacetylation. Nature Metabolism, 2021, 3, 196-210.	11.9	29
6	Difference in risk factors of silent brain infarction between paroxysmal and persistent atrial fibrillation. IJC Heart and Vasculature, 2021, 33, 100753.	1.1	1
7	Increased oxidative stress during exercise predicts poor prognosis in patients with acute decompensated heart failure. ESC Heart Failure, 2021, 8, 3885-3893.	3.1	8
8	A simple method of sarcopenia detection can predict adverse cardiovascular events in patients with abdominal obesity. International Journal of Obesity, 2021, 45, 2214-2220.	3.4	8
9	Soluble urokinase-type plasminogen activator receptor represents exercise tolerance and predicts adverse cardiac events in patients with heart failure. Heart and Vessels, 2020, 35, 681-688.	1.2	3
10	Analysis of the driving mechanism in paroxysmal atrial fibrillation: comparison of the activation sequence between the left atrial body and pulmonary vein. Journal of Cardiology, 2020, 75, 673-681.	1.9	1
11	Associations between corrected serum calcium and phosphorus levels and outcome in dialysis patients in the Kumamoto Prefecture. Hemodialysis International, 2020, 24, 202-211.	0.9	8
12	H 2 FPEF score for predicting future heart failure in stable outpatients with cardiovascular risk factors. ESC Heart Failure, 2020, 7, 66-75.	3.1	16
13	Comprehensive assessment of takotsubo cardiomyopathy by cardiac computed tomography. Emergency Radiology, 2019, 26, 109-112.	1.8	7
14	Prognostic significance of polyvascular disease in heart failure with preserved left ventricular ejection fraction. Medicine (United States), 2019, 98, e15959.	1.0	12
15	Coronary blood flow volume change is negatively associated with platelet aggregability in patients with non-obstructive ischemic heart disease who have no anti-platelet agents. International Journal of Cardiology, 2019, 277, 3-7.	1.7	1
16	Grip strength predicts cardiac adverse events in patients with cardiac disorders: an individual patient pooled meta-analysis. Heart, 2019, 105, 834-841.	2.9	61
17	Nonâ€Val30Met mutation, septal hypertrophy, and cardiac denervation in patients with mutant transthyretin amyloidosis. ESC Heart Failure, 2019, 6, 122-130.	3.1	12
18	Reply to letter to the editor: "A simple sarcopenia screening test predicts future adverse events in patients with heart failure― International Journal of Cardiology, 2018, 256, 28.	1.7	0

#	Article	IF	CITATIONS
19	Impact of Chronic Kidney Disease on Outcomes After Percutaneous Coronary Intervention for Chronic Total Occlusions (from the Japanese Multicenter Registry). American Journal of Cardiology, 2018, 121, 1519-1523.	1.6	8
20	Non-invasive testing for sarcopenia predicts future cardiovascular events in patients with chronic kidney disease. International Journal of Cardiology, 2018, 268, 216-221.	1.7	45
21	Clinical Usefulness of Dual-Energy Cardiac Computed Tomography in Acute Coronary Syndrome Using a Dual-Layer Spectral Detector Scanner. Circulation: Cardiovascular Imaging, 2018, 11, e007277.	2.6	1
22	Outcome of current and history of cancer on the risk of cardiovascular events following percutaneous coronary intervention: a Kumamoto University Malignancy and Atherosclerosis (KUMA) study. European Heart Journal Quality of Care & Clinical Outcomes, 2018, 4, 290-300.	4.0	53
23	Evaluation of Collateral Source Characteristics With 3â€Dimensional Analysis Using Micro–Xâ€Ray Computed Tomography. Journal of the American Heart Association, 2018, 7, .	3.7	2
24	Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis. ESC Heart Failure, 2018, 5, 27-35.	3.1	56
25	Recent advances in diagnosis and treatment of cardiac amyloidosis. Journal of Cardiology, 2018, 71, 135-143.	1.9	39
26	Coronary Artery Plaque Regression by a PCSK9 Antibody and Rosuvastatin in Double-heterozygous Familial Hypercholesterolemia with an <i>LDL Receptor</i> Mutation and a <i>PCSK9</i> V4I Mutation. Internal Medicine, 2018, 57, 3551-3557.	0.7	7
27	Akt1-Mediated Muscle Growth Promotes Blood Flow Recovery After Hindlimb Ischemia by Enhancing Heme Oxygenase-1 in Neighboring Cells. Circulation Journal, 2018, 82, 2905-2912.	1.6	8
28	Tailored Adjunctive Cilostazol Therapy Based on CYP2C19 Genotyping in Patients With Acute Myocardial Infarction ― The CALDERA-GENE Study ―. Circulation Journal, 2018, 82, 1517-1525.	1.6	9
29	Analysis for the primary predictive factor for the incidence of esophageal injury after ablation of atrial fibrillation. Journal of Cardiology, 2018, 72, 480-487.	1.9	2
30	Impact of statin-ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease — Sub-analysis of PRECISE-IVUS trial. International Journal of Cardiology, 2018, 268, 23-26.	1.7	5
31	Fetal Origins of Hypertension. Advances in Experimental Medicine and Biology, 2018, 1012, 41-48.	1.6	6
32	Dose-dependent INhibitory effect of rosuVastatin In Japanese patienTs with Acute myocardial infarcTION on serum concentration of matrix metalloproteinases – INVITATION trial. Journal of Cardiology, 2018, 72, 350-355.	1.9	3
33	CYP2C19 variants and epoxyeicosatrienoic acids in patients with microvascular angina. IJC Heart and Vasculature, 2017, 15, 15-20.	1.1	9
34	Successful treatment of deep vein thrombosis caused by iliac vein compression syndrome with a single-dose direct oral anti-coagulant. Thrombosis Journal, 2017, 15, 4.	2.1	5
35	Effects of the Mean Amplitude of Glycemic Excursions and Vascular Endothelial Dysfunction on Cardiovascular Events in Nondiabetic Patients With Coronary Artery Disease. Journal of the American Heart Association, 2017, 6, .	3.7	21
36	Lenvatinib, an oral multi-kinases inhibitor, -associated hypertension: Potential role of vascular endothelial dysfunction. Atherosclerosis, 2017, 260, 116-120.	0.8	33

#	Article	IF	CITATIONS
37	Prognostic Value of the CHADS ₂ Score for Adverse Cardiovascular Events in Coronary Artery Disease Patients Without Atrial Fibrillation—A Multiâ€Center Observational Cohort Study. Journal of the American Heart Association, 2017, 6, .	3.7	17
38	A case of pulmonary thromboembolism due to coagulation factor V Leiden in Japan ~ usefulness of next generation sequencing~. Thrombosis Journal, 2017, 15, 8.	2.1	3
39	Reduced trans-mitral A-wave velocity predicts the presence of wild-type transthyretin amyloidosis in elderly patients with left ventricular hypertrophy. Heart and Vessels, 2017, 32, 708-713.	1.2	3
40	Cardioprotective Effects of LCZ696Â(Sacubitril/Valsartan) After ExperimentalÂAcuteÂMyocardial Infarction. JACC Basic To Translational Science, 2017, 2, 655-668.	4.1	63
41	When Is the Optimal Timing of Surgical Intervention for Severe Functional Tricuspid Regurgitation?. Case Reports in Cardiology, 2017, 2017, 1-4.	0.2	0
42	Colchicine Improves Survival, Left Ventricular Remodeling, and Chronic Cardiac Function After Acute Myocardial Infarction. Circulation Journal, 2017, 81, 1174-1182.	1.6	82
43	Pulmonary Tumor Thrombotic Microangiopathy ― Antemortem Diagnosis With Pulmonary Artery Wedge Blood Cell Sampling in a Recurrent Breast Cancer Patient ―. Circulation Journal, 2017, 81, 1959-1960.	1.6	6
44	Clinical and morphological presentations of acute coronary syndrome without coronary plaque rupture — An intravascular ultrasound study. International Journal of Cardiology, 2016, 220, 112-115.	1.7	2
45	Association of CYP2C19 variants and epoxyeicosatrienoic acids on patients with microvascular angina. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 311, H1409-H1415.	3.2	12
46	Impaired Peripheral Endothelial Function Assessed by Digital Reactive Hyperemia Peripheral Arterial Tonometry and Risk of In‧tent Restenosis. Journal of the American Heart Association, 2016, 5, .	3.7	8
47	Helicobacter Pylori-seropositivity along with genetic and environmental factors predicts clinical outcome after acute coronary syndrome. International Journal of Cardiology, 2016, 212, 54-56.	1.7	2
48	More haste, less speed: Cardiac perforation by a thoracentesis catheter. IJC Heart and Vasculature, 2016, 11, 17-18.	1.1	2
49	A simple sarcopenia screening test predicts future adverse events in patients with heart failure. International Journal of Cardiology, 2016, 215, 301-306.	1.7	55
50	Prevalence of coronary macro- and micro-vascular dysfunctions after drug-eluting stent implantation without in-stent restenosis. International Journal of Cardiology, 2016, 222, 185-194.	1.7	16
51	Fragmented QRS complex is a diagnostic tool in patients with left ventricular diastolic dysfunction. Heart and Vessels, 2016, 31, 563-567.	1.2	20
52	High serum levels of thrombospondin-2 correlate with poor prognosis of patients with heart failure with preserved ejection fraction. Heart and Vessels, 2016, 31, 52-59.	1.2	30
53	Patients with both CYP2C19 loss-of-function allele and peripheral endothelial dysfunction are significantly correlated with adverse cardiovascular events following coronary stent implantation. Journal of Cardiology, 2016, 67, 104-109.	1.9	9
54	Differential impact of peripheral endothelial dysfunction on subsequent cardiovascular events following percutaneous coronary intervention between chronic kidney disease (CKD) and non-CKD patients. Heart and Vessels, 2016, 31, 1038-1044.	1.2	5

#	Article	IF	CITATIONS
55	Helicobacter pylori Seropositivity in Patients with Interleukin-1 Polymorphisms Is Significantly Associated with ST-Segment Elevation Myocardial Infarction. PLoS ONE, 2016, 11, e0166240.	2.5	19
56	Distribution of Ankle-Brachial Index among Inpatients with Cardiovascular Disease: Analysis Using the Kumamoto University Hospital Medical Database. Annals of Vascular Diseases, 2016, 9, 22-29.	0.5	4
57	Expression of Let-7 family microRNAs in skin correlates negatively with severity of pulmonary hypertension in patients with systemic scleroderma. IJC Heart and Vasculature, 2015, 8, 98-102.	1.1	19
58	Physiological basis of discordance between coronary flow velocity reserve and hyperemic microvascular resistance for evaluating coronary microvascular dysfunction in patients without atherosclerotic obstruction. International Journal of Cardiology, 2015, 201, 535-537.	1.7	6
59	Determinants of Myocardial Lactate Production During Acetylcholine Provocation Test in Patients With Coronary Spasm. Journal of the American Heart Association, 2015, 4, .	3.7	8
60	Telmisartan enhances mitochondrial activity and alters cellular functions in human coronary artery endothelial cells via AMP-activated protein kinase pathway. Atherosclerosis, 2015, 239, 375-385.	0.8	17
61	Sirt7 Contributes to Myocardial Tissue Repair by Maintaining Transforming Growth Factor-Î ² Signaling Pathway. Circulation, 2015, 132, 1081-1093.	1.6	88
62	Significance of Low Plasma Levels of Brain-Derived Neurotrophic Factor in Patients With Heart Failure. American Journal of Cardiology, 2015, 116, 243-249.	1.6	57
63	ST-segment elevation myocardial infarction in a patient with anomalous origin of left circumflex coronary artery. Journal of Cardiology Cases, 2015, 11, 120-123.	0.5	2
64	Impact of left ventricular hypertrophy on impaired coronary microvascular dysfunction. International Journal of Cardiology, 2015, 187, 411-413.	1.7	8
65	Acetylcholine-Provoked Coronary Spasm at Site of Significant Organic Stenosis Predicts Poor Prognosis in Patients With Coronary Vasospastic Angina. Journal of the American College of Cardiology, 2015, 66, 1105-1115.	2.8	59
66	Tissue Inhibitor of Metalloproteinase-3 Knockout Mice Exhibit Enhanced Energy Expenditure through Thermogenesis. PLoS ONE, 2014, 9, e94930.	2.5	6
67	Akt1-Mediated Fast/Glycolytic Skeletal Muscle Growth Attenuates Renal Damage in Experimental Kidney Disease. Journal of the American Society of Nephrology: JASN, 2014, 25, 2800-2811.	6.1	49
68	Lower Framingham risk score and the absence of hypertension are associated with the morning peak in the circadian variation of ST-elevation myocardial infarction onset. Hypertension Research, 2014, 37, 239-245.	2.7	0
69	Correlation Between Extent of Myocardial Fibrosis Assessed by Cardiac Magnetic Resonance and Cardiac Troponin T Release in Patients With Nonischemic Heart Failure. American Journal of Cardiology, 2014, 113, 1697-1704.	1.6	19
70	Gender differences in impact of vascular endothelial dysfunction on clinical outcome following coronary stenting in patients with coronary heart disease. International Journal of Cardiology, 2014, 177, 723-725.	1.7	2
71	Growth Differentiation Factor-15 Is a Useful Prognostic Marker in Patients With Heart Failure With Preserved Ejection Fraction. Canadian Journal of Cardiology, 2014, 30, 338-344.	1.7	64
72	Akt1–Mediated Skeletal Muscle Growth Attenuates Cardiac Dysfunction and Remodeling After Experimental Myocardial Infarction. Circulation: Heart Failure, 2012, 5, 116-125.	3.9	36

#	Article	IF	CITATION
73	Chronic C-Type Natriuretic Peptide Infusion Attenuates Angiotensin II-Induced Myocardial Superoxide Production and Cardiac Remodeling. International Journal of Vascular Medicine, 2012, 2012, 1-9.	1.0	36
74	Long-term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris. Atherosclerosis, 2011, 214, 415-421.	0.8	35
75	FGF21 is an Aktâ€regulated myokine. FEBS Letters, 2008, 582, 3805-3810.	2.8	344
76	Fast/Glycolytic Muscle Fiber Growth Reduces Fat Mass and Improves Metabolic Parameters in Obese Mice. Cell Metabolism, 2008, 7, 159-172.	16.2	331
77	Follistatin-like 1, a Secreted Muscle Protein, Promotes Endothelial Cell Function and Revascularization in Ischemic Tissue through a Nitric-oxide Synthase-dependent Mechanism. Journal of Biological Chemistry, 2008, 283, 32802-32811.	3.4	258
78	Vascular Endothelial Growth Factor Blockade Promotes the Transition From Compensatory Cardiac Hypertrophy to Failure in Response to Pressure Overload. Hypertension, 2006, 47, 887-893.	2.7	292
79	Apoptosis Signal-Regulating Kinase 1 Plays a Pivotal Role in Angiotensin II–Induced Cardiac Hypertrophy and Remodeling. Circulation Research, 2003, 93, 874-883.	4.5	217